Related Experiment Video
Updated: Jun 9, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease
1Division of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, California, USA. ndvaziri@uci.edu
Insights
Chronic kidney disease (CKD) accelerates atherosclerosis by altering lipid metabolism and high-density lipoprotein (HDL) function. These changes promote cardiovascular disease and kidney damage, even with standard treatments.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Lipid Metabolism
Background:
- Chronic kidney disease (CKD) significantly increases cardiovascular disease (CVD) risk.
- CKD is linked to inflammation, oxidative stress, and dyslipidemia, driving atherosclerosis.
- CKD dyslipidemia involves low HDL, impaired HDL function, and altered lipoprotein profiles.
Purpose of the Study:
- To review the impact of CKD on HDL structure and function.
- To examine lipid metabolism pathways in CKD affecting the kidney and vasculature.
- To discuss the limitations of current therapies in managing CKD-associated CVD.
Main Methods:
- Review of existing literature on CKD, dyslipidemia, and atherosclerosis.
- Analysis of lipid accumulation in rat models of CKD.
- Examination of molecular pathways regulating lipid transport and metabolism in CKD.
Main Results:
- CKD induces lipid accumulation in kidneys and aortas of rats.
- Lipid accumulation is mediated by altered expression of lipid transport and metabolism proteins.
- Impaired HDL function and dysregulated lipid pathways promote atherosclerosis and kidney damage.
Conclusions:
- CKD profoundly affects HDL and lipid metabolism, contributing to CVD and kidney disease progression.
- Statins and antioxidants have limited efficacy in end-stage renal disease populations.
- Understanding these pathways is crucial for developing targeted therapies for CKD-associated cardiovascular complications.
Abstract:
Chronic kidney disease (CKD) is associated with a high risk of death from cardiovascular disease. Inflammation, oxidative stress, and dyslipidemia, which are common consequences of CKD, contribute to the pathogenesis of atherosclerosis and cardiovascular disease in this population. Dyslipidemia of CKD is characterized by diminished plasma high density lipoprotein (HDL) concentration, impaired HDL anti-oxidant and anti-inflammatory activities, and elevated plasma triglyceride, very low density lipoprotein (VLDL), intermediate density lipoprotein, chylomicron remnants, and oxidized lipids and lipoproteins. The constellation of inflammation, HDL deficiency, and oxidative modification of lipoproteins can cause atherosclerosis and progression of renal disease. We have recently found lipid accumulation in the remnant kidney and the wall of aorta in rats with CKD induced by 5/6 nephrectomy. This was mediated by up-regulation of scavenger receptors involved in the influx of oxidized lipids or lipoproteins, tubular reabsorption of lipid binding proteins through megalin-cubilin complexes, upregulation of fatty acid synthesis, and downregulation of fatty acid oxidation pathways. The combination of increased lipid influx, elevated production and reduced catabolism of lipids, and impaired HDL-mediated reverse cholesterol transport can promote atherosclerosis, glomerulosclerosis, and tubulointerstitial damage. Although statins can be effective in slowing CKD progression in patients with mild-to-moderate CKD, they have consistently failed to mitigate oxidative stress, inflammation, HDL deficiency, or cardiovascular mortality in the end-stage renal disease populations. Similarly, high doses of antioxidant vitamins have failed to either ameliorate oxidative stress, inflammation, or improve overall mortality in end-stage renal disease. This article is intended to provide a brief review of the effects of CKD on HDL structure and function and pathways of lipid influx, efflux, synthesis, and catabolism in the artery wall and the diseased kidney.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Kidney Disease III: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
